BOLMANN BROS. LLC – Trademark Portfolio

Entity Type: 16

BOLMANN BROS. LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include COFFEELLAGEN and BOLMANN BROTHERS. The owner is based in SAN ANTONIO, TX.

4903 S FLORES ST

SAN ANTONIO, TX 78214

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BOLMANN BROS. LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does BOLMANN BROS. LLC have?

BOLMANN BROS. LLC has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.

What trademark classes does BOLMANN BROS. LLC file in?

BOLMANN BROS. LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BOLMANN BROS. LLC's most well-known trademarks?

BOLMANN BROS. LLC's registered trademark portfolio includes well-known marks such as COFFEELLAGEN and BOLMANN BROTHERS. These are among 2 currently registered trademarks in the portfolio.

What is BOLMANN BROS. LLC's trademark registration success rate?

BOLMANN BROS. LLC has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.